Document is current
Any future updates will be listed below
-
Authors
Lin, Qing
Zhou, Dawei
Ma, Jiawei
Zhao, Jingwei
Chen, Guangqiang
Wu, Lei
Li, Tong
Zhao, Shangfeng
Wen, Honglin
Yu, Huixian
Zhang, Shaolan
Gao, Kai
Yang, Rongli
Shi, Guangzhi https://orcid.org/0000-0003-4189-5800
-
Funding
Funding for this research was provided by:
Yangfan Project for Key Medical Programs from the Hospital Authority of Beijing (ZYLX202109)
- License Information
-
More Information
Article History
Received: 30 December 2023
Accepted: 10 April 2024
First Online: 8 August 2024
Conflicts of Interest
: No conflicts of interest were reported for this study.
: The research protocol of this experiment and the informed consent of the study participants have been approved by the Ethics Committee of Tiantan Hospital Affiliated with Capital Medical University of China (Ethics review number KY 2021-087-01). Researchers explain the study plan in detail to all patients or their legal representatives and obtain written informed consent. Before they agree to participate in the trial and sign the informed consent form, information will be provided, including the natural history, treatment procedures, risks, possible consequences, and costs of subarachnoid hemorrhage. At any stage of the study, each patient has the right to request a withdrawal. Trial results will be disseminated via publications, conference presentations, and the media. During the study, the patient’s name was replaced by a number to protect the patient’s privacy. Copies of the study participant’s code catalog, informed consent forms, case report forms, and relevant diagnostic test data, as well as drug handling records, are kept for 2 years after the termination of the clinical trial. Entered electronic data are kept for life.
